Esperion Therapeutics (ESPR) saw its stock price plummet 6.12% in pre-market trading on Thursday following the release of its third-quarter financial results for 2025. The biopharmaceutical company's earnings report revealed figures that fell significantly short of analysts' expectations, triggering a sell-off among investors.

The company reported a net loss of $31.333 million for the quarter, which was more than double the estimated loss of $14.5 million projected by IBES. Similarly, Esperion's operating loss came in at $9.959 million, far exceeding the anticipated loss of $1.53 million. These figures underscore the company's ongoing struggle to achieve profitability, despite reporting product sales of $40.659 million for the quarter.

Adding to investor concerns, Esperion posted a basic earnings per share (EPS) of -$0.16, reflecting the company's financial challenges. The report also revealed operating expenses of $97.268 million, a figure that overshadows the company's product sales and raises questions about its cost management strategies. As Esperion continues to navigate these financial hurdles, the market's reaction suggests growing impatience among shareholders waiting for signs of a turnaround in the company's fortunes.